A randomised clinical trial investigating the effect of pembrolizumab, lenalidomide, dexametahsone versus lenalidomide, dexamethasone in newly diagnosed and treatment naïve Multiple Myeloma who are ineligible for autologous stem cell transplant
| Studied treatment |
pembrolizumab, lenalidomide and low-dose dexamethasone |
| Control treatment | lenalidomide and low-dose dexamethasone |
| Patients | newly diagnosed and treatment naïve Multiple Myeloma who are ineligible for autologous stem cell transplant |
| Group sizes | 151 / 150 |
Only 301 of the 640 planned had been enrolled when the trial was halted
| Blindness | open-design | Inclusion period | |
| Follow-up duration | Centers | ||
| Lost to FU | geographical localisation | ||
| Primary endpoint | Design | Parallel groups |
All trials of pembrolizumab, lenalidomide, dexametahsone
Appears in following systematic reviews:
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
